A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CDK / cyclin-dependent kinase

[Related PubMed/MEDLINE]
Total Number of Papers: 3585
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CDK  (>> Co-occurring Abbreviation)
Long Form:   cyclin-dependent kinase
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. MBC, RECIST, TEAE
2022 Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. ---
2022 Aberrant GIMAP2 expression affects oral squamous cell carcinoma progression by promoting cell cycle and inhibiting apoptosis. GIMAP2, OSCC
2022 An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors. GBM, HEK293T, PDGFRA, VUS
2022 Auxin-Glucose Conjugation Protects the Rice (Oryza sativa L.) Seedlings Against Hydroxyurea-Induced Phytotoxicity by Activating UDP-Glucosyltransferase Enzyme. ABA, APX, CAT, CTK, CYC, GA, HU, IAA, MDA, POD, RNR, ROS, SA, SOD, UGT
2022 Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. ---
2022 CDK activity sensors: genetically encoded ratiometric biosensors for live analysis of the cell cycle. ---
2022 CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. ---
2022 CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR. CCK-8, ESCC, mTOR, p-DNA-PKcs
10  2022 CDK4/6 inhibitors: a brief overview and prospective research directions. PROTAC
11  2022 CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. ER, HER2, PR, TNBC
12  2022 CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. AdvSM, MC
13  2022 Centriole distal-end proteins CP110 and Cep97 influence centriole cartwheel growth at the proximal end. MT, PLK4
14  2022 Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. GEO, HCC, HR, MST, RT-qPCR
15  2022 Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase. HR, Plk1
16  2022 Coordinating gene expression during the cell cycle. FOXM1, Rb, TFs
17  2022 Cyclin-dependent kinase 1 depolymerizes nuclear lamin filaments by disrupting the head-to-tail interaction of the lamin central rod domain. ---
18  2022 Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. WT
19  2022 Cyclin-Dependent Kinase 4/6 Inhibitors Against Breast Cancer. ---
20  2022 Cyclin-Dependent Kinase 4/6 Inhibitors: A Potential Breakthrough Therapy for Malignancies of Gastrointestinal Tract. ---
21  2022 Cyclin-Dependent Kinase 4/6 Inhibitors: Is a Noncanonical Substrate the Key Target? ---
22  2022 Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition. ---
23  2022 Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. GEO, GO, ICD, ICP, KEGG, ssGSEA, TNBC, WGCNA
24  2022 Cyclin-dependent kinases in DNA damage response. DDR, DSBR, HR, NHEJ
25  2022 Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway. ALDH1A1, BC, Bmi1, FoxM1
26  2022 Discovery of novel inhibitors of CDK2 using docking and physics-based binding free energy calculation. ---
27  2022 Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer. AR
28  2022 Effect of miR-144-3p-Targeted Regulation of PTEN on Proliferation, Apoptosis, and Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells under Stretch. ALP, BAX, Bcl-2, BMSCs, CCK-8, PTEN, qRT-PCR, WB
29  2022 ESMO 2021-my top three abstracts in breast cancer. ADCs, CPS, ESMO, HR, OS, PFS
30  2022 Established and experimental systemic treatment options for advanced liposarcoma. ALT/WDLPS, DDLPS, MDM2, MLPS, PLPS, PPARgamma, STSs
31  2022 Everolimus for Treating Hormone Receptor-positive Metastatic Breast Cancer Previously Treated With Cyclin-dependent Kinase 4/6 Inhibitors. HER2, mTOR
32  2022 Extracellular vesicle-mediated co-delivery of TRAIL and dinaciclib for targeted therapy of resistant tumors. EV, TRAIL
33  2022 From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy. ---
34  2022 Identification of the AccCDK1 gene in Apis cerana cerana and its relationship with the oxidative stress response. AccCDK1, CAT, POD, SOD
35  2022 Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression. ---
36  2022 Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer. PCa
37  2022 Inhibition of Cyclin-Dependent Kinase 9 Downregulates Cytokine Production Without Detrimentally Affecting Human Monocyte-Derived Macrophage Viability. MDMs
38  2022 Inhibition of DEK Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia Cells. CDK6, DEK, DOX, T-ALL
39  2022 Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials. AEs, CIs, ILD, Peto ORs, RCTs
40  2022 Intra-S phase checkpoint kinase Chk1 dissociates replication proteins Treslin and TopBP1 through multiple mechanisms during replication stress. Chk1
41  2022 Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis. BL, DLBCL, EBV, RNA-Seq
42  2022 Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer. Rb
43  2022 Lymphostatin, a virulence factor of attaching and effacing Escherichia coli, inhibits proliferation and cytokine responses of human T cells in a manner associated with cell cycle arrest but not apoptosis or necrosis. EPEC, PBMCs
44  2022 Management of human epidermal growth factor receptor 2-negative metastatic breast cancer: Role of poly adenosine diphosphate (ADP-ribose) polymerase inhibitors. BC, ET, gBRCAm, HER2, HR, MBCs
45  2022 MiR-132-3p inhibits proliferation, invasion and migration of colorectal cancer cells via down-regulating FOXP2 expression. CDK1, CRC, FOX, miR, MMP
46  2022 Natural Plant Compounds: Does Caffeine, Dipotassium Glycyrrhizinate, Curcumin, and Euphol Play Roles as Antitumoral Compounds in Glioblastoma Cell Lines? CHOP, DPG, DR, GBM, miRs, NF-kappaB, ROCK, TIMP-1
47  2022 Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. HER2, HR, IBC-NST, IHC, NE, NEC, NENs, NETs, WHO
48  2022 Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. BM
49  2022 Palbociclib Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells via RB-Independent STAT3 Phosphorylation. LUSC, RB, STAT3
50  2022 Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review. ABC, CHEERS, MBC
51  2022 Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity. JAK, PI3K, ROCK2
52  2022 Plantamajoside Attenuates Neointima Formation via Upregulation of Tissue Inhibitor of Metalloproteinases in Balloon-Injured Rats. BI, MMP, PMS, TIMP, VSMC
53  2022 Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. LMS, PDX
54  2022 Prediction of allosteric druggable pockets of cyclin-dependent kinases. NetPocket
55  2022 Proteomic and Phosphoproteomic Analyses Reveal Gibel Carp Responses to Cyprinid Herpesvirus 2 Infection. CKII, CyHV-2, HVHND, IMAC, iTRAQ
56  2022 Pulmonary Delivery of Extracellular Vesicle-Encapsulated Dinaciclib as an Effective Lung Cancer Therapy. Dina, EV-T, TRAIL
57  2022 Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer. EOC, Pur, ROS
58  2022 Reciprocal regulation of p21 and Chk1 controls the cyclin D1-RB pathway to mediate senescence onset after G2 arrest. ---
59  2022 Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation. ---
60  2022 Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells. TSGs
61  2022 Stepping on the molecular brake: Slowing down proliferation to allow differentiation. SMR4
62  2022 Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer. BOR, ET, MBC, PFS
63  2022 Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. ---
64  2022 Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis. AFP
65  2022 Targeting CDK7 in oncology: The avenue forward. ---
66  2022 Targeting Cyclin-Dependent Kinase 7 - Association between CDK7 and pMED1 Expression in Prostate Cancer Tissue. AR, DM, LNM, MED1, PCa, pTUR, RP
67  2022 Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. AKT, AR, ICIs, MMR, PARP, PCa, PSMA, WNT
68  2022 The cyclin-dependent kinase inhibitor p27Kip1 interacts with the aryl hydrocarbon receptor and negatively regulates its transcriptional activity. AhR
69  2022 The pro-tumorigenic activity of p38γ overexpression in nasopharyngeal carcinoma. GEPIA, NPC, Rb
70  2022 The Renaissance of Cyclin Dependent Kinase Inhibitors. ---
71  2022 The Role of CDK Pathway Dysregulation and Its Therapeutic Potential in Soft Tissue Sarcoma. STSs
72  2022 Thromboembolic Events in Patients with HER2-Negative, Hormone Receptor-Positive, Metastatic Breast Cancer Treated with Ribociclib Combined with Letrozole or Fulvestrant: A Real-World Data. CVST, HER2, HR, MBC, TEE
73  2022 Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors. TGCT
74  2022 Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation. alpha-SMA, anti-CD117, CT, HE, HP, HPFs, IF, MRI, PET, US
75  2022 VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. BCL2, BCLXL, CBR, CI, ER, PFS
76  2022 Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review. ---
77  2021 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells. 4-AAQB, DDR, TNBC
78  2021 A biomimetic assay platform for the interrogation of antigen-dependent anti-tumor T-cell function. BRD, IO, MHC
79  2021 A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC). AKIs, EGFR, HNSCC, HNSCCs, HTS, NCI, NIH, NMRC, TKIs
80  2021 A Crosstalk Between Dual-Specific Phosphatases and Dual-Specific Protein Kinases Can Be A Potential Therapeutic Target for Anti-cancer Therapy. CLK, DUSPs, DYRKs, MAPKs, MKPs, mTOR, mTORC1, PI3K, PTKs, PTPs
81  2021 A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer. MBC, mPFS, ORR, OS, PFS
82  2021 A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. AD, CTC, mHSPC, PFS, RR
83  2021 A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. CI, gBRCA, gBRCAm, MBC, OS, sHR, TFST
84  2021 ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. ---
85  2021 Activation of CDC25A phosphatase is limited by CDK2/cyclin A-mediated feedback inhibition. ---
86  2021 Activation of Smad2/3 signaling by low fluid shear stress mediates artery inward remodeling. BMP, EC, FSS, TGF
87  2021 Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. AR, ER, HER2, PDX, TNBC
88  2021 Advances in Oral Oncolytic Agents for Breast Cancer and Recommendations for Promoting Adherence. ---
89  2021 AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. ---
90  2021 Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. CDK9
91  2021 Analyzing the scaffold diversity of cyclin-dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. ---
92  2021 Anti-Atherosclerotic Effect of Gossypetin on Abnormal Vascular Smooth Muscle Cell Proliferation and Migration. GTIN, MMP, NF-kappaB, PKB, Rb, ROS, VSMCs
93  2021 Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential. BA, Bax, cdc, MMP, PARP, ROS
94  2021 Budding yeast relies on G1 cyclin specificity to couple cell cycle progression with morphogenetic development. ---
95  2021 Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy. HER, ICI
96  2021 CDK 4/6 inhibitor induced lung injury: a case report and review of literature. ---
97  2021 CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. VTE
98  2021 Cell cycle inertia underlies a bifurcation in cell fates after DNA damage. ---
99  2021 Cell Cycle Regulatory Protein Expression in Multinucleated Giant Cells of Giant Cell Tumor of Bone: do They Proliferate? GCs, GCTB
100  2021 Cellular microRNA-127-3p suppresses oncogenic herpesvirus-induced transformation and tumorigenesis via down-regulation of SKP2. KSHV, miRNAs, mRNA